期刊
TUMOR BIOLOGY
卷 37, 期 8, 页码 10269-10278出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-016-4816-5
关键词
TRAIL; TrichostatinA; FOXM1; ERK; Gastric cancer; Combination therapy
类别
资金
- National Nature Science Foundation of China [81402308, 81301874]
- Natural Science Foundation of Beijing [7132051]
- 985 special project - Peking University Health Science Center [2013-5-09]
- Ministry of Science and Technology of the People's Republic of China [2014AA020603]
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an ideal apoptosis inducer and believed to have promise in cancer therapy, yet part of cancer cells exhibit resistance to TRAIL-mediated apoptosis. This necessitates the exploration of agents that resensitizes cancer cells to TRAIL. In our study, we found that Trichostatin A (TSA), an histone deacetylase (HDAC) inhibitor, augmented TRAIL-induced apoptosis in gastric cancer cells in a caspase-dependent manner. Besides, upregulation of DR5 and downregulation of anti-apoptotic proteins including XIAP, Mcl-1, Bcl-2 and Survivin also contributed to this synergism. Noticeably, TSA treatment inhibited Forkhead boxM1 (FOXM1), which expression lcing of FOXM1 by small interfering RNA (siRNA) resensitized cancer cells to TRAIL and strengthened the TRAIL-augmenting effect of TSA. In addition, we demonstrated the depletion of FOXM1 was a consequence of the inactivation of ERK mediated by TSA. Collectively, it was first shown that TSA potentiated TRAIL sensitivity via ERK/FOXM1 pathway in gastric cancer cells. FOXM1 might serve as a biomarker for predicting sensitivity to TRAIL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据